Navigation Links
FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Date:10/16/2007

PRINCETON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of IXEMPRA(TM) (ixabepilone) as monotherapy for the treatment of patients with metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine. The FDA has also granted approval of IXEMPRA in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline, and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. IXEMPRA is a microtubule inhibitor belonging to a class of antineoplastic agents, the epothilones. Bristol-Myers Squibb anticipates that IXEMPRA will be available within days.

"Previously, patients with aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies had limited treatment options," said Linda Vahdat, M.D., Associate Professor of Clinical Medicine and Associate Attending Physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The approval of IXEMPRA means that we now have an important new option for patients with metastatic breast cancer who have rapidly progressed through currently approved chemotherapies."

"Bristol-Myers Squibb has a rich history in oncology spanning more than 40 years, and we are extremely proud that IXEMPRA has been approved as it is a significant addition to the Bristol-Myers Squibb oncology portfolio and addresses a serious unmet medical need in the treatment of patients with metastatic or locally a
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. Analog people in the Digital Revolution, part II
9. Analog people in the digital revolution
10. Unique Surface Treatment of Novel TSK-GEL ODS Columns Provide Separation of Aqueous and Fat Soluble Vitamins
11. Improve Recovery and Reproducibility with Pre-Treatment of Analytical TSK-GEL G3000SWXL Size Exclusion Columns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... technologies besides fluorescence in situ hybridization (FISH), ... Molecular cytogenetics includes application of nanobiotechnology, microarrays, ...
(Date:9/2/2015)... CUMBERLAND, R.I. , Sept. 2, 2015 /PRNewswire/ ... has been enrolled in the multicenter Phase 2 ... for the long-term treatment of recurrent subfoveal choroidal ... AMD).  NT-503 is a unique vascular endothelial growth ... versatile ECT implant. "This landmark proof-of-concept ...
(Date:9/2/2015)... SAN FRANCISCO, Calif. , Sept. 2, 2015 /PRNewswire/ ... that Bonnie H. Anderson , president and chief ... Healthcare Conference on Wednesday, September 16, 2015 at 10:30 ... . The live audio webcast and ... http://investor.veracyte.com . The webcast will be available shortly after ...
(Date:9/2/2015)... Biovista Inc. freut sich, ... 2015 bekanntgeben zu können. Hierbei handelt es sich ... Biovista unterstützt mit seiner Möglichkeit der Analyse ... Krankheiten als denen, für die ein Medikament ursprünglich ... Team bei der Wylder Nation Foundation bei der ...
Breaking Biology Technology:Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... (Nasdaq: MNKD ), focused on discovering, developing and,commercializing ... present at the UBS Global Life Sciences Conference on ... Hyatt Hotel in New York, NY. Interested parties ... of the,presentation in the Investor Relations section of the ...
... Sept. 18 InterMune, Inc.,(Nasdaq: ITMN ) today ... other conditions, 3,000,000 shares of its common stock in ... underwriters,a 30-day option to purchase up to an additional ... All of the shares in the offering,will be sold ...
... Sept. 18 /PRNewswire-FirstCall/-- Biodel Inc. (Nasdaq:,BIOD) today ... program,at the 43rd Scientific Sessions of the ... VIAject(TM) Phase II meal study data ... entitled, "Pharmacokinetics and pharmacodynamics of,insulin VIAject(TM), insulin ...
Cached Biology Technology:InterMune Announces Proposed Public Offering of Common Stock 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 2Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting 3
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare.    "Over the ...
(Date:8/18/2015)... DUBLIN , Aug. 17, 2015 ... the addition of the "Global Biometric Authentication ... Application - Estimation & Forecast, 2015-2020" report ... biometric authentication and identification systems market is expected ... from 2015 to 2020 and generate over $25 ...
(Date:8/12/2015)... 12, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that four of its fingerprint ID ... officially been named FIDO Certified™ by the Fast ... certification, Synaptics, Natural ID™ fingerprint solutions are fully ... (UAF) standard and are interoperable among other products ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... of fish we buy in stores or order in restaurants, the ... than dying of natural causes. This may seem obvious to most ... not be apparent is that the relentless pursuit of consumer-friendly fish ... world. By repeatedly choosing only the biggest fish, or only those ...
... at San Antonio (UTSA) has received a five-year, $2.7 ... study nanomaterials and their biomedical applications. The NSF ... Materials grant, is the second major NSF award announced ... receipt of $5 million to establish a computer-based research ...
... available in French . Montreal, September 10, ... hide when exposed to stressful environmental conditions. So how do ... the journal Proceedings of the National Academy of Sciences ... keep dangerous gene alterations in check to ensure their continued ...
Cached Biology News:Changing the course of nature: Are fisheries directing the evolution of fish populations? 2UTSA Physics Department receives $2.7 million to study nanomaterials 2Evolution coup: Study reveals how plants protect their genes 2
Mouse polyclonal antibody raised against a partial recombinant MHC2TA. NCBI Entrez Gene ID = 4261...
Mouse monoclonal antibody raised against a partial recombinant NR4A2. NCBI Entrez Gene ID = NR4A2...
... Sight DS-L2 imaging controller is a successor ... and allows users to comfortably observe, record ... controller features an 8.4 inch LCD (XGA) ... of Nikon cameras including the DS-Fi1 , ...
... DNA Technologies also offers a DNA sequencing ... templates including plasmids, PCR products, BACs, etc. ... templates such as purified plasmids or purified ... handling robotics optimized for automated reaction setup ...
Biology Products: